Total biosynthesis of the cyclic AMP booster forskolin from Coleus forskohlii

  1. Irini Pateraki  Is a corresponding author
  2. Johan Andersen-Ranberg
  3. Niels Bjerg Jensen
  4. Sileshi Gizachew Wubshet
  5. Allison Maree Heskes
  6. Victor Forman
  7. Björn Hallström
  8. Britta Hamberger
  9. Mohammed Saddik Motawia
  10. Carl Erik Olsen
  11. Dan Staerk
  12. Jørgen Hansen
  13. Birger Lindberg Møller
  14. Bjoern Hamberger
  1. University of Copenhagen, Denmark
  2. University of California, Berkeley, United States
  3. Evolva, Denmark
  4. Nofima, Norway
  5. KTH - Royal Institute of Technology, Sweden
  6. Michigan State University, United States

Abstract

Forskolin is a unique structurally complex labdane type diterpenoid used in the treatment of glaucoma and heart failure based on its activity as a cyclic AMP booster. Commercial production of forskolin relies exclusively on extraction from its only known natural source, the plant Coleus forskohlii, in which forskolin accumulates in the root cork. Here we report the discovery of five cytochrome P450s and two acetyltransferases which catalyze a cascade of reactions converting the forskolin precursor 13R-manoyl oxide into forskolin and a diverse array of additional labdane-type diterpenoids. A minimal set of three P450s in combination with a single acetyl transferase was identified that catalyzes the conversion of 13R-manoyl oxide into forskolin as demonstrated by transient expression in Nicotiana benthamiana. The entire pathway for forskolin production from glucose encompassing expression of nine genes was stably integrated into Saccharomyces cerevisiae and afforded forskolin titers of 40 mg/L.

Article and author information

Author details

  1. Irini Pateraki

    Plant Biochemistry Laboratory, Department of Plant and Environmental Sciences, University of Copenhagen, Copenhagen, Denmark
    For correspondence
    eipa@plen.ku.dk
    Competing interests
    Irini Pateraki, Filed international patent600 applications (PCT/DK2015/050020) covering 'Biosynthesis of forskolin and related compounds.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7526-2334
  2. Johan Andersen-Ranberg

    Department of Plant and Microbial Biology, University of California, Berkeley, Berkeley, United States
    Competing interests
    Johan Andersen-Ranberg, Filed international patent600 applications (PCT/DK2015/050020) covering 'Biosynthesis of forskolin and related compounds.
  3. Niels Bjerg Jensen

    Evolva, Copenhagen, Denmark
    Competing interests
    Niels Bjerg Jensen, Filed international patent600 applications (PCT/DK2015/050020) covering 'Biosynthesis of forskolin and related compoundsEmployee of Evolva SA.
  4. Sileshi Gizachew Wubshet

    Nofima, Osloveien, Norway
    Competing interests
    No competing interests declared.
  5. Allison Maree Heskes

    Plant Biochemistry Laboratory, Department of Plant and Environmental Sciences, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2732-5185
  6. Victor Forman

    Plant Biochemistry Laboratory, Department of Plant and Environmental Sciences, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
  7. Björn Hallström

    Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden
    Competing interests
    No competing interests declared.
  8. Britta Hamberger

    Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, United States
    Competing interests
    No competing interests declared.
  9. Mohammed Saddik Motawia

    Plant Biochemistry Laboratory, Department of Plant and Environmental Sciences, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
  10. Carl Erik Olsen

    Plant Biochemistry Laboratory, Department of Plant and Environmental Sciences, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
  11. Dan Staerk

    Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
  12. Jørgen Hansen

    Evolva, Copenhagen, Denmark
    Competing interests
    Jørgen Hansen, Employee of Evolva SA.
  13. Birger Lindberg Møller

    Plant Biochemistry Laboratory, Department of Plant and Environmental Sciences, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    Birger Lindberg Møller, Filed international patent600 applications (PCT/DK2015/050020) covering 'Biosynthesis of forskolin and related compounds.
  14. Bjoern Hamberger

    Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, United States
    Competing interests
    Bjoern Hamberger, Filed international patent600 applications (PCT/DK2015/050020) covering 'Biosynthesis of forskolin and related compounds'.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1249-1807

Funding

Villum Fonden

  • Birger Lindberg Møller

Novo Nordisk

  • Birger Lindberg Møller

European Commission

  • Irini Pateraki

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2017, Pateraki et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,235
    views
  • 839
    downloads
  • 102
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Irini Pateraki
  2. Johan Andersen-Ranberg
  3. Niels Bjerg Jensen
  4. Sileshi Gizachew Wubshet
  5. Allison Maree Heskes
  6. Victor Forman
  7. Björn Hallström
  8. Britta Hamberger
  9. Mohammed Saddik Motawia
  10. Carl Erik Olsen
  11. Dan Staerk
  12. Jørgen Hansen
  13. Birger Lindberg Møller
  14. Bjoern Hamberger
(2017)
Total biosynthesis of the cyclic AMP booster forskolin from Coleus forskohlii
eLife 6:e23001.
https://doi.org/10.7554/eLife.23001

Share this article

https://doi.org/10.7554/eLife.23001

Further reading

    1. Biochemistry and Chemical Biology
    Nelson García-Vázquez, Tania J González-Robles ... Michele Pagano
    Research Article

    In healthy cells, cyclin D1 is expressed during the G1 phase of the cell cycle, where it activates CDK4 and CDK6. Its dysregulation is a well-established oncogenic driver in numerous human cancers. The cancer-related function of cyclin D1 has been primarily studied by focusing on the phosphorylation of the retinoblastoma (RB) gene product. Here, using an integrative approach combining bioinformatic analyses and biochemical experiments, we show that GTSE1 (G-Two and S phases expressed protein 1), a protein positively regulating cell cycle progression, is a previously unrecognized substrate of cyclin D1–CDK4/6 in tumor cells overexpressing cyclin D1 during G1 and subsequent phases. The phosphorylation of GTSE1 mediated by cyclin D1–CDK4/6 inhibits GTSE1 degradation, leading to high levels of GTSE1 across all cell cycle phases. Functionally, the phosphorylation of GTSE1 promotes cellular proliferation and is associated with poor prognosis within a pan-cancer cohort. Our findings provide insights into cyclin D1’s role in cell cycle control and oncogenesis beyond RB phosphorylation.

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Mai Nguyen, Elda Bauda ... Cecile Morlot
    Research Article

    Teichoic acids (TA) are linear phospho-saccharidic polymers and important constituents of the cell envelope of Gram-positive bacteria, either bound to the peptidoglycan as wall teichoic acids (WTA) or to the membrane as lipoteichoic acids (LTA). The composition of TA varies greatly but the presence of both WTA and LTA is highly conserved, hinting at an underlying fundamental function that is distinct from their specific roles in diverse organisms. We report the observation of a periplasmic space in Streptococcus pneumoniae by cryo-electron microscopy of vitreous sections. The thickness and appearance of this region change upon deletion of genes involved in the attachment of TA, supporting their role in the maintenance of a periplasmic space in Gram-positive bacteria as a possible universal function. Consequences of these mutations were further examined by super-resolved microscopy, following metabolic labeling and fluorophore coupling by click chemistry. This novel labeling method also enabled in-gel analysis of cell fractions. With this approach, we were able to titrate the actual amount of TA per cell and to determine the ratio of WTA to LTA. In addition, we followed the change of TA length during growth phases, and discovered that a mutant devoid of LTA accumulates the membrane-bound polymerized TA precursor.